By Ian Walker

GSK PLC raised its full-year guidance after third-quarter net profit rose, although it missed analysts' forecasts.

The British pharmaceutical giant attributed its strong performance mainly to the launch of its first respiratory syncytial virus vaccine, Arexvy, in the U.S.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

November 01, 2023 03:35 ET (07:35 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos GSK.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos GSK.